stockrowDr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
Follow RDY
Alert me
Dr. Reddy's Laboratories Ltd (RDY) Operating cash flow
Dr. Reddy's Laboratories Ltd's operating cash flow for fiscal 2026 was $607.0M, up 11.4% from $545.0M in fiscal 2025. Over the twelve months to 30 September 2026 it was $313.0M. Over the past ten years it has ranged from $277.0M (fiscal 2018) to $716.0M (fiscal 2023); the current reading is higher than 83% of that period. Dr. Reddy's Laboratories Ltd ranks 12th of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2026 | $607.0M | 11.38% |
| FY2025 | $545.0M | 0.00% |
| FY2024 | $545.0M | (23.88%) |
| FY2023 | $716.0M | 93.51% |
| FY2022 | $370.0M | (24.18%) |
| FY2021 | $488.0M | 23.23% |
| FY2020 | $396.0M | (4.58%) |
| FY2019 | $415.0M | 49.82% |
| FY2018 | $277.0M | (16.57%) |
| FY2017 | $332.0M | (46.71%) |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $56.0M | — |
| Jun 2026 | −$10.0M | — |
| Mar 2026 | $149.0M | 26.27% |
| Dec 2025 | $118.0M | (30.18%) |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| VTRS Viatris Inc. compare | $2.5B |
| NBIX Neurocrine Biosciences, Inc. compare | $1.1B |
| ELAN Elanco Animal Health Incorporated compare | $617.0M |
| LNTH Lantheus Holdings, Inc. compare | $409.5M |
| RDY Dr. Reddy's Laboratories Ltd | $313.0M |
| HIMS Hims & Hers Health, Inc. compare | $263.5M |
| ALKS Alkermes plc compare | $243.0M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $198.8M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $180.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on RDY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement